65 related articles for article (PubMed ID: 17764779)
21. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Teramoto K; Asada Y; Ozaki Y; Suzumura Y; Nakano Y; Sawai S; Tezuka N; Inoue S; Fujino S
Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
[TBL] [Abstract][Full Text] [Related]
22. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
23. Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients ageWeissman CH; Sandbach J; Brooker R; Vellek M; Lindquist D; Conkling P; Ilegbodu D; Asmar L
Lung Cancer; 2006 Jun; 52(3):313-7. PubMed ID: 16621129
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Manegold C; Gravenor D; Woytowitz D; Mezger J; Hirsh V; Albert G; Al-Adhami M; Readett D; Krieg AM; Leichman CG
J Clin Oncol; 2008 Aug; 26(24):3979-86. PubMed ID: 18711188
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Nugent FW; Mertens WC; Graziano S; Levitan N; Collea R; Gajra A; Marshall J; McCann J
Lung Cancer; 2005 May; 48(2):267-73. PubMed ID: 15829328
[TBL] [Abstract][Full Text] [Related]
26. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Vázquez S; Huidobro G; Amenedo M; Fírvida JL; León L; Lázaro M; Grande C; Mel JR; Ramos M; Salgado M; Casal J
Anticancer Drugs; 2007 Nov; 18(10):1201-6. PubMed ID: 17893521
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
Jiang L; Wang DY; Zhu ZH; Tang LF; Hou XH; Zhao HD; Xie Z; Wang DF
Cancer Chemother Pharmacol; 2010 Aug; 66(3):449-53. PubMed ID: 19937029
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Chen YM; Perng RP; Tsai CM; Whang-Peng J
Lung Cancer; 2006 Jun; 52(3):333-8. PubMed ID: 16554106
[TBL] [Abstract][Full Text] [Related]
29. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
[TBL] [Abstract][Full Text] [Related]
30. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
Chen YM; Perng RP; Shih JF; Whang-Peng J
Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).
Görn M; Habermann CR; Anige M; Thöm I; Schuch G; Andritzky B; Brandl S; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C; Laack E
Onkologie; 2008 Apr; 31(4):185-9. PubMed ID: 18418020
[TBL] [Abstract][Full Text] [Related]
32. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.
Chen YM; Liu JM; Chou TY; Perng RP; Tsai CM; Whang-Peng J
Cancer; 2007 May; 109(9):1821-8. PubMed ID: 17351950
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M
Clin Lung Cancer; 2012 Nov; 13(6):505-9. PubMed ID: 22853980
[TBL] [Abstract][Full Text] [Related]
34. Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Juan Ó; Aparisi F; Sánchez-Hernández A; Muñoz-Langa J; Esquerdo G; García-Sánchez J; López A; Garde J; Giner V
Clin Lung Cancer; 2015 May; 16(3):193-9. PubMed ID: 25547902
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
Camps C; Massuti B; Jiménez A; Maestu I; Gómez RG; Isla D; González JL; Almenar D; Blasco A; Rosell R; Carrato A; Viñolas N; Batista N; Girón CG; Galán A; López M; Blanco R; Provencio M; Diz P; Felip E;
Ann Oncol; 2006 Mar; 17(3):467-72. PubMed ID: 16371411
[TBL] [Abstract][Full Text] [Related]
36. Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum.
Seto T; Yamanaka T; Nakano M; Ota M; Maruyama R; Okamoto T; Wataya H; Uematsu K; Seki N; Eguchi K; Semba H; Ichinose Y
J Thorac Oncol; 2008 Jun; 3(6):637-42. PubMed ID: 18520804
[TBL] [Abstract][Full Text] [Related]
37. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.
Chen YM; Fan WC; Tsai CM; Liu SH; Shih JF; Chou TY; Wu CH; Chou KT; Lee YC; Perng RP; Whang-Peng J
J Thorac Oncol; 2011 Jun; 6(6):1110-6. PubMed ID: 21415778
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Lara PN; Longmate J; Reckamp K; Gitlitz B; Argiris A; Ramalingam S; Belani CP; Mack PC; Lau DH; Koczywas M; Wright JJ; Shepherd FA; Leighl N; Gandara DR
Clin Lung Cancer; 2011 Jan; 12(1):33-7. PubMed ID: 21273177
[TBL] [Abstract][Full Text] [Related]
39. Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Cortinovis D; Bidoli P; Cullurà D; Lorusso V; Ardizzoia A; Amoroso V; Bandera M; Aitini E; Fusi A; Zilembo N; Radula D; Bajetta E
J Thorac Oncol; 2008 Apr; 3(4):405-11. PubMed ID: 18379360
[TBL] [Abstract][Full Text] [Related]
40. [A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy].
Wang ZP; Sun Y; Zhang XR; Zhang MH; Wang XW; Yu XJ; Nan KJ; Li EX; Liu JW; Gao YJ; Guan XQ; Song SP; Sheng LJ; Wang DL; Wang ZX
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):465-8. PubMed ID: 19024525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
